- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Multiple myeloma
- Meeting Date: July 2020
- Public Summary Document (PSD) July 2020 PBAC Meeting - (PDF 983KB)
- Public Summary Document (PSD) July 2020 PBAC Meeting - (Word 80KB)
Carfilzomib – July 2020
Carfilzomib: Powder for injection 10 mg, Powder for injection 30 mg, Powder for injection 60 mg; Kyprolis®
Last updated
30 October 2020